Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in active primary Sjogren's Syndrome
NCT05673993Phase 3Completed
- Sponsor
- RemeGen
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telitacicept (3 arms), sponsored by RemeGen. Primary endpoint: EULAR Sjogren's Syndrome Disease Activity Index at 24 weeks. Started Apr 2023; status: completed.
02
Drugs
telitacicept
Beyond the preview
Go deeper on NCT05673993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673993.